J Vet Sci.  2015 Dec;16(4):467-473. 10.4142/jvs.2015.16.4.467.

Immunization of BALB/c mice with Brucella abortus 2308DeltawbkA confers protection against wild-type infection

Affiliations
  • 1College of Animal Science and Technology, Shihezi University, Shihezi 832000, China. allanzhh@sohu.com
  • 2School of life sciences, Shangqiu normal university, Shangqiu 476000, China.
  • 3College of Biology, Agriculture and Forestry, Tongren University, Tongren 554300, China.
  • 4Co-Innovation Center for Zoonotic Infectious Diseases in the Western Region, Shihezi University, Shihezi 832000, China.
  • 5College of Medicine, Shihezi University, Shihezi 832000, China.

Abstract

Brucellosis is a zoonotic disease that causes animal and human diseases. Vaccination is a major measure for prevention of brucellosis, but it is currently not possible to distinguish vaccinated animals from those that have been naturally infected. Therefore, in this study, we constructed the Brucella (B.) abortus 2380 wbkA mutant (2308DeltawbkA) and evaluated its virulence. The survival of 2308DeltawbkA was attenuated in murine macrophage (RAW 264.7) and BALB/c mice, and it induced high protective immunity in mice. The wbkA mutant elicited an anti-Brucella-specific immunoglobulin G response and induced the secretion of gamma interferon. Antibodies to 2308DeltawbkA could be detected in sera from mice, implying the potential for use of this protein as a diagnostic antigen. The WbkA antigen would allow serological differentiation between infected and vaccinated animals. These results suggest that 2308DeltawbkA is a potential attenuated vaccine against 16M. This vaccine will be further evaluated in sheep.

Keyword

2308DeltawbkA; Brucella; vaccine

MeSH Terms

Animals
Antibodies
Brucella abortus*
Brucella*
Brucellosis
Humans
Immunization*
Immunoglobulin G
Interferons
Macrophages
Mice*
Sheep
Staphylococcal Protein A
Vaccination
Virulence
Zoonoses
Antibodies
Immunoglobulin G
Interferons
Staphylococcal Protein A

Figure

  • Fig. 1 Intracellular replication of Brucella abortus 2380 wbkA mutant (2308ΔwbkA) within RAW264.7 macrophages. RAW264.7 Macrophages were infected with 2308ΔwbkA, S19, 2308-wbkA and S2308 at a multiplicity of infection of 150. The level of initial infection was the same for these strains. At 4, 8, 24 and 48 h post-infection, infected macrophages were lysed and bacteria were calculated by plating serial dilutions on tryptone soy agar plates. The results demonstrate that the 2308ΔwbkA was unable to achieve the level of colonization reached by the conventional vaccine strain S19, parental strain S2308 and complementary strain 2308-wbkA. Significant differences between the mutant and S2308 or 2308-wbkA are indicated by *p < 0.05 and **p < 0.01.

  • Fig. 2 Clearance of 2308ΔwbkA after infection. BALB/c mice were inoculated i.p. with 1 × 106 CFU/mouse of 2308ΔwbkA, S19 and S2308. Control groups were inoculated i.p. with phosphate buffered saline (PBS). Infected mice were sacrificed by CO2 asphyxiation at 3, 7, 14, 21 and 28 days post-infection, after which spleens were removed aseptically and assessed individually for colonization. Values are the means ± SD (n = 5 per time point). Differences in splenic colonization were determined by one-way ANOVA. *p < 0.05, **p < 0.01.

  • Fig. 3 Anti-Brucella in serum from mice immunized with 2308ΔwbkA or S19. Mice were inoculated i.p. with 1 × 106 CFU of 2308ΔwbkA or S19. Control groups were inoculated with PBS. Serum samples were collected at 3, 7, 14, 21 and 28 days post-vaccination (n = 5 per time point) and IgG antibodies were determined by enzyme-linked immunosorbent assay (ELISA). The results are the means ± SD of the absorbance at 450 nm (OD450). Significant differences between the 2308ΔwbkA and PBS groups are indicated by *p < 0.05.

  • Fig. 4 IFN-γ production by spleen cells of BALB/c mice vaccinated with 2308ΔwbkA or S19. Spleens from mice were inoculated i.p. with 1 × 106 CFU of 2308ΔwbkA or S19. Control groups were inoculated with PBS. At 4 weeks post-vaccination, mice were euthanized and splenocytes were recovered and stimulated with either heat-killed S2308, concanavalin A (ConA) or RPMI 1640. Splenocyte culture supernatants were harvested and analysis of IFN-γ secretion (pg/mL) was assayed by ELISA. Significant differences from the same stimulus in PBS-injected mice are indicated by *p < 0.05.

  • Fig. 5 Response of WbkA to 2308ΔwbkA immunization sera. Sera from mice immunized with 2308ΔwbkA, S2308, S19 and PBS were collected. Antibodies to WbkA were detected in these sera by Western blotting. Antibodies against the WbkA protein were not detected in sera from 2308ΔwbkA immunized mice.

  • Fig. 6 Humoral immune responses to WbkA were assessed in serum by indirect ELISA. Sera from mice immunized with 2308ΔwbkA, S2308, S19 and PBS were collected. Humoral immune responses against the WbkA protein were not detected in serum from 2308ΔwbkA immunized mice.


Cited by  1 articles

Interaction between Brucella melitensis 16M and small ubiquitin-related modifier 1 and E2 conjugating enzyme 9 in mouse RAW264.7 macrophages
Jihai Yi, Yueli Wang, Qifeng Li, Huan Zhang, Zhiran Shao, XiaoYu Deng, Jinke He, Chencheng Xiao, Zhen Wang, Yong Wang, Chuangfu Chen
J Vet Sci. 2019;20(5):.    doi: 10.4142/jvs.2019.20.e54.


Reference

1. Adone R, Ciuchini F, Marianelli C, Tarantino M, Pistoia C, Marcon G, Petrucci P, Francia M, Riccardi G, Pasquali P. Protective properties of rifampin-resistant rough mutants of Brucella melitensis. Infect Immun. 2005; 73:4198–4204.
Article
2. Ashford DA, di Pietra J, Lingappa J, Woods C, Noll H, Neville B, Weyant R, Bragg SL, Spiegel RA, Tappero J, Perkins BA. Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51. Vaccine. 2004; 22:3435–3439.
Article
3. Bercovich Z. The use of skin delayed-type hypersensitivity as an adjunct test to diagnose brucellosis in cattle: a review. Vet Q. 2000; 22:123–130.
Article
4. Berkelman RL. Human illness associated with use of veterinary vaccines. Clin Infect Dis. 2003; 37:407–414.
Article
5. Cardoso PG, Macedo GC, Azevedo V, Oliveira SC. Brucella spp noncanonical LPS: structure, biosynthesis, and interaction with host immune system. Microb Cell Fact. 2006; 5:13.
6. Crasta OR, Folkerts O, Fei Z, Mane SP, Evans C, Martino-Catt S, Bricker B, Yu G, Du L, Sobral BW. Genome sequence of Brucella abortus vaccine strain S19 compared to virulent strains yields candidate virulence genes. PLoS One. 2008; 3:e2193.
7. Davis DS, Elzer PH. Brucella vaccines in wildlife. Vet Microbiol. 2002; 90:533–544.
8. Delrue RM, Lestrate P, Tibor A, Letesson JJ, De Bolle X. Brucella pathogenesis, genes identified from random large-scale screens. FEMS Microbiol Lett. 2004; 231:1–12.
9. Goel D, Bhatnagar R. Intradermal immunization with outer membrane protein 25 protects Balb/c mice from virulent B. abortus 544. Mol Immunol. 2012; 51:159–168.
Article
10. Golding B, Scott DE, Scharf O, Huang LY, Zaitseva M, Lapham C, Eller N, Golding H. Immunity and protection against Brucella abortus. Microbes Infect. 2001; 3:43–48.
11. Grilló MJ, Manterola L, de Miguel MJ, Muñoz PM, Blasco JM, Moriyón I, López-Goñi I. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants. Vaccine. 2006; 24:2910–2916.
Article
12. Haag AF, Myka KK, Arnold MF, Caro-Hernández P, Ferguson GP. Importance of lipopolysaccharide and cyclic β-1,2-glucans in Brucella-mammalian infections. Int J Microbiol. 2010; 2010:124509.
13. Hernández-Castro R, Verdugo-Rodríguez A, Puente JL, Suárez-Güemes F. The BMEI0216 gene of Brucella melitensis is required for internalization in HeLa cells. Microb Pathog. 2008; 44:28–33.
Article
14. Liu WX, Hu S, Qiao ZJ, Chen WY, Liu LT, Wang FK, Hua RH, Bu ZG, Li XR. Expression, purification, and improved antigenic specificity of a truncated recombinant bp26 protein of Brucella melitensis M5-90: a potential antigen for differential serodiagnosis of brucellosis in sheep and goats. Biotechnol Appl Biochem. 2011; 58:32–38.
15. Moriyón I, Grilló MJ, Monreal D, González D, Marín C, López-Goñi I, Mainar-Jaime RC, Moreno E, Blasco JM. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res. 2004; 35:1–38.
Article
16. Sathiyaseelan J, Goenka R, Parent M, Benson RM, Murphy EA, Fernandes DM, Foulkes AS, Baldwin CL. Treatment of Brucella-susceptible mice with IL-12 increases primary and secondary immunity. Cell Immunol. 2006; 243:1–9.
Article
17. Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Vet Microbiol. 2002; 90:479–496.
Article
18. Silva TMA, Paixão TA, Costa EA, Xavier MN, Sá JC, Moustacas VS, den Hartigh AB, Carvalho Neta AV, Oliveira SC, Tsolis R, Santos RL. Putative ATP-binding cassette transporter is essential for Brucella ovis pathogenesis in mice. Infect Immun. 2011; 79:1706–1717.
Article
19. Wang Y, Bai Y, Qu Q, Xu J, Chen Y, Zhong Z, Qiu Y, Wang T, Du X, Wang Z, Yu S, Fu S, Yuan J, Zhen Q, Yu Y, Chen Z, Huang L. The 16MΔvjbR as an ideal live attenuated vaccine candidate for differentiation between Brucella vaccination and infection. Vet Microbiol. 2011; 151:354–362.
Article
20. Wang Y, Chen Z, Qiao F, Ying T, Yuan J, Zhong Z, Zhou L, Du X, Wang Z, Zhao J, Dong S, Jia L, Yuan X, Yang R, Sun Y, Huang L. Comparative proteomics analyses reveal the virB of B. melitensis affects expression of intracellular survival related proteins. PLoS One. 2009; 4:e5368.
21. Zhang J, Guo F, Chen C, Li Z, Zhang H, Wang Y, Zhang K, Du G, Li Y, Wang J, Jian T, Wang Z. Brucella melitensis 16MΔhfq attenuation confers protection against wild-type challenge in BALB/c mice. Microbiol Immunol. 2013; 57:502–510.
22. Zhong Z, Wang Y, Qiao F, Wang Z, Du X, Xu J, Zhao J, Qu Q, Dong S, Sun Y, Huang L, Huang K, Chen Z. Cytotoxicity of Brucella smooth strains for macrophages is mediated by increased secretion of the type IV secretion system. Microbiology. 2009; 155:3392–3402.
Article
Full Text Links
  • JVS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr